ArticleHaematologica2020
Erdheim-Chester disease with concomitant Rosai-Dorfman like lesions: a distinct entity mainly driven by
Abstract readLetter
In one paragraph
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- An Overlap of Erdheim-Chester Disease and Rosai-Dorfman Disease With Isolated Bone Lesions Presenting a Diagnostic Challenge: A Case Report.Clinical case reports · 2026Article
- Histiocytosis development and clinical variation through the lens of genomics.The Journal of pathology · 2026Review
- [A rare case of Rosai-Dorfman disease involving the pituitary stalk and presenting initially with diabetes insipidus].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Clinicopathological insights into ophthalmic Rosai-Dorfman disease: A 15-year retrospective analysis.Indian journal of ophthalmology · 2026Article
- The xanthogranuloma family of histiocytic neoplasms in the molecular era: Erdheim-Chester disease and beyond.Hematology. American Society of Hematology. Education Program · 2025Review
- Article
- NTRK1-rearranged histiocytosis: clinicopathologic and molecular features.Blood advances · 2025Article
- Recent advances in therapeutic strategies of Erdheim-Chester disease.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder.The Journal of clinical endocrinology and metabolism · 2025Review
- IgG4-related disease and other fibro-inflammatory conditions.Nature reviews. Rheumatology · 2025Review
- Head and neck hematolymphoid proliferations: what is new?Pathologica · 2025Review
- BRAF V600E mutation and high expression of PD-L1 in Rosai-Dorfman disease: case report and review of the literature.Journal of hematopathology · 2024Review
- Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms.Blood advances · 2024Article
- Rosai-Dorfman-Destombes disease in adults: a single center experience.Annals of hematology · 2024Article
- Distinct [European journal of nuclear medicine and molecular imaging · 2024Article
- Clinical phenotype of adult-onset systemic histiocytosis harboringHaematologica · 2024Article
- Lenalidomide and dexamethasone for Rosai-Dorfman disease: a single arm, single center, prospective phase 2 study.EClinicalMedicine · 2024Article
- Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy.British journal of haematology · 2024Article
- Liquid biopsy of cerebrospinal fluid enabling the detection and therapeutic targeting of the BRAFJournal of neurology · 2024Article
- Histiocytic neoplasm subtypes differ in their MAP2K1 mutational type.Blood advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Jérôme RazanamaheryInternal Medicine Department 2, Assistance Publique-Hôpitaux de Paris, French National Reference Center for Histiocytoses, Pitié-Salpêtrière Hospital, Paris, France.
Eli L DiamondDepartment of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Fleur Cohen-AubartInternal Medicine Department 2, Assistance Publique-Hôpitaux de Paris, French National Reference Center for Histiocytoses, Pitié-Salpêtrière Hospital, Paris, France.
Karl-Heinz PlateInstitute of Neurology, Goethe University Hospital, Frankfurt Cancer Institute, German Consortium for Translational Cancer Research, Frankfurt, Germany.
Giota LouridaDepartment of Internal Medicine and Infectious Disease, Sotiria Hospital, Athens, Greece.
Frederic CharlotteDepartment of Pathology, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France.
Zofia Hélias-RodzewiczPathology Service, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris Boulogne, Paris, France.
Gaurav GoyalDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Ronald S GoDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Ahmet DoganDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Omar Abdel-WahabDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Benjamin DurhamDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Neval OzkayaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zahir AmouraInternal Medicine Department 2, Assistance Publique-Hôpitaux de Paris, French National Reference Center for Histiocytoses, Pitié-Salpêtrière Hospital, Paris, France.
Jean-Francois EmilePathology Service, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris Boulogne, Paris, France.
Julien HarocheInternal Medicine Department 2, Assistance Publique-Hôpitaux de Paris, French National Reference Center for Histiocytoses, Pitié-Salpêtrière Hospital, Paris, France julien.haroche@aphp.fr.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MAnatomic Pathology Residency ProgramZIEBC011384 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BARR, FREDERIC · 2011 to 2025
$26.8MOrigins of BRAF-mutant hematologic malignancies and their therapeutic resistanceR01CA201247 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, PARK, CHRISTOPHER Y · 2016 to 2020
$2.7MCellular Origins, Molecular Pathogenesis, and Novel Therapeutic Strategies for MAP Kinase-Driven Hematological MalignanciesK08CA218901 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DURHAM, BENJAMIN HEATH · 2018 to 2022
$1.0MNCI NIH HHS K08 CA218901NCI NIH HHS L30 CA231804NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA201247
Abstract
PubMed holds no abstract for this paper.
Indexed as
Erdheim-Chester DiseaseAdultAgedAged, 80 and overDiagnosis, DifferentialFemaleHumansMaleMAP Kinase Kinase 1Middle AgedMAP2K1 protein, humanMAP Kinase Kinase 1
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.